Von Willebrand Factor in Pregnancy (VIP) Study (VIP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04146376 |
|
Recruitment Status :
Recruiting
First Posted : October 31, 2019
Last Update Posted : January 28, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding.
This is a prospective, open-label, cohort study in women with VWD using Wilate VWF replacement therapy to maintain trough or minimum VWF levels of 100-150% for delivery and the immediate postpartum period, followed by levels of 50-100% for 5-10 days after delivery, depending upon the route of delivery. The primary objective is to document the rate of primary postpartum hemorrhage (PPH). The secondary objective is to document further effectiveness outcomes and safety.
| Condition or disease | Intervention/treatment |
|---|---|
| Von Willebrand Diseases | Other: Use of a postpartum diary and additional blood draws Drug: VWF replacement therapy with Wilate Drug: Tranexamic acid Other: Use of a postpartum diary and additional blood draws. |
For pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels > 50-100%, specific guidance is lacking for delivery planning for how high a VWF level should be achieved. Specifically, guidance is lacking on whether VWF replacement therapy should target a VWF minimum level in the 100-150% range, i.e., a range closer to the 200-250% levels observed in normal pregnancy.
This is a prospective, open-label, cohort study using Wilate VWF replacement therapy, trough or minimum VWF levels of 100-150% will be maintained for delivery in women with VWD whose third trimester VWF levels are <100%. This group is termed "non-correctors". Women with VWD whose third trimester VWF levels spontaneously rise to >100% will be assigned to the "corrector" group, and these women will not receive VWF replacement therapy. All patients will receive tranexamic acid for 14 days postpartum. Outcome parameters will be assessed for all patients.
The investigators or qualified research personnel will approach all consecutive pregnant VWD patients until 65 non-corrector patients have completed the study protocol, and up to 30 corrector patients have completed the study protocol. Patients with gestational week 34-38 von Willebrand factor activity (VWF:Act) or von Willebrand factor ristocetin cofactor (VWF:RCo), and/or Factor VIII procoagulant activity (FVIII:C) less than 100 percent will be used to assign patients to the non-corrector group. When VWF collagen binding (VWF:CB) laboratory monitoring can be performed, patients with an isolated VWF:CB type 2 defect can also be enrolled.
Rate of primary postpartum hemorrhage, severe postpartum hemorrhage, secondary postpartum hemorrhage will be measured. Safety and secondary laboratory measures will be assessed.
| Study Type : | Observational |
| Estimated Enrollment : | 110 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Von Willebrand Factor in Pregnancy (VIP) Study: A Multicenter Study of Wilate Use in Von Willebrand Disease for Childbirth |
| Actual Study Start Date : | October 12, 2019 |
| Estimated Primary Completion Date : | June 2023 |
| Estimated Study Completion Date : | June 2023 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Non-Corrector
Patients with gestational week 34-38 von Willebrand factor activity, or von Willebrand factor ristocetin cofactor, or Factor VIII procoagulant activity less than 100 percent will be termed non-correctors. When laboratory monitoring can be performed, patients with an isolated von Willebrand factor collagen binding type 2 defect, von Willebrand factor collagen binding less than 100 percent can also be enrolled and determined as a non-corrector.
|
Other: Use of a postpartum diary and additional blood draws
A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules. Several blood draws additional to what is expected for routine clinical care will also be taken. Drug: VWF replacement therapy with Wilate This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are <100% in the third trimester of pregnancy Drug: Tranexamic acid This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD |
|
Corrector
Patients with von Willebrand factor parameter levels greater than or equal to 100 percent self-corrected at gestational weeks 34-38 will be termed correctors.
|
Drug: Tranexamic acid
This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD Other: Use of a postpartum diary and additional blood draws. A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules. Several blood draws additional to what is expected for routine clinical care will also be taken. |
- rate of primary postpartum hemorrhage (PPH) [ Time Frame: within 24 hours postpartum ]estimated blood loss greater than or equal to 1000 mL, or severe PPH defined as estimated blood loss greater than 2000 mL within 24 hours postpartum, as indicated by: visual estimation, pre- and post- weight of blood soaked materials, photospectrometry
- rate of secondary postpartum hemorrhage (PPH) [ Time Frame: 24 hours to 6 weeks postpartum ]excessive blood loss: any transfusions not anticipated in the antepartum birth plan, including number and type of blood products transfused within 48 hours after treatment, any transfusions not anticipated in the antepartum birth plan, including number and type of blood products transfused beyond 48 hours after treatment, change in antepartum hemoglobin, change in pictorial blood assessment chart (PBAC) score, number of patients needing interventions for bleeding (e.g., use of Bakri balloon, angiographic embolization, B-Lynch sutures, surgical arterial ligation, or hysterectomy for persistent bleeding), iron levels (serum iron, TIBC, and ferritin) 6 weeks postpartum
- occurrence of venous or arterial thrombus [ Time Frame: up to 42 days postpartum ]clinically documented venous or arterial thrombus
- occurrence of infusion-related reactions [ Time Frame: up to 42 days postpartum ]clinically documented infusion-related reactions
- laboratory assessment of efficacy and VWF replacement [ Time Frame: up to 42 days postpartum ]central laboratory assessment of VWF parameters relative to bleeding
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- von Willebrand Disease (VWD) patients defined prepartum as Type 1 per National Heart, Lung, and Blood Institute (NHLBI) criterion of von Willebrand Factor (VWF) level less than 30 percent, or Type 2, or Type 3
- VWF and Factor VIII (FVIII) levels obtained in gestational weeks 34-38 will determine enrollment in the non-corrector or corrector group:
- Patients with gestational week 34-38 VWF:Ag, VWF:Act (or VWF:RCo), or FVIII:Act less than 100 percent will be enrolled in the non-corrector group. In patients with an isolated VWF:CB type 2 defect, VWF:CB less than 100 percent can also be determined as a non-corrector
- Patients with VWF parameter levels greater than or equal to 100 percent self-corrected at gestational weeks 34-38 will be enrolled in the corrector group
- Written informed consent from the patient prepartum, before gestational week 39
Exclusion Criteria:
- Presence of other concurrent disorder of hemostasis, platelet dysfunction, or collagen disorders
- Presence of liver disease or renal disease, clinical suspicion or diagnosis of preeclampsia or eclampsia, HELLP syndrome, TTP, DIC, or other acquired vasculopathy or coagulopathy
- Age less than 18 years
- Inability of the local laboratory to monitor the VWF laboratory tests needed during the course of treatment to determine Wilate dosing adjustments
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04146376
| Contact: Sarah Ruuska, MPH | 206-689-6193 | sarahru@bloodworksnw.org |
| United States, Illinois | |
| Bleeding & Clotting Disorders Institute | Recruiting |
| Peoria, Illinois, United States, 61615 | |
| Contact: Jonathan Roberts, MD 309-692-5337 jroberts@ilbcdi.org | |
| Principal Investigator: Jonathan Roberts, MD | |
| United States, Louisiana | |
| Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders | Recruiting |
| New Orleans, Louisiana, United States, 70112 | |
| Contact: Melody Benton, MPH, MAS, CCRP 504-988-3596 mbenton@tulane.edu | |
| Principal Investigator: Maissaa Janbain, MD | |
| United States, Washington | |
| Washington Center for Bleeding Disorders at Bloodworks | Recruiting |
| Seattle, Washington, United States, 98104 | |
| Contact: Sarah Ruuska, MPH 206-689-6193 sarahru@bloodworksnw.org | |
| Principal Investigator: Jill Johnsen, MD | |
| Principal Investigator: | Jill M Johnsen, M.D. | Bloodworks | |
| Principal Investigator: | Barbara A Konkle, M.D. | Bloodworks | |
| Principal Investigator: | Peter A Kouides, M.D. | Mary M. Gooley Hemophilia Center |
| Responsible Party: | Jill Johnsen, Associate Member, Bloodworks Northwest Research Institute, Bloodworks |
| ClinicalTrials.gov Identifier: | NCT04146376 |
| Other Study ID Numbers: |
VIPStudy |
| First Posted: | October 31, 2019 Key Record Dates |
| Last Update Posted: | January 28, 2021 |
| Last Verified: | January 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
von Willebrand Disease von Willebrand Factor postpartum hemorrhage |
|
Von Willebrand Diseases Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases Coagulation Protein Disorders Blood Platelet Disorders Hemorrhagic Disorders |
Genetic Diseases, Inborn Tranexamic Acid Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants |